Kidpik Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ezra Dabah
- Full Time Employees
- 14
- Sector
- Consumer Cyclical
- Industry
- Specialty Retail
- Address
- 200 Park Avenue South New York City NY United States of America 10003
- IPO Date
- Nov 11, 2021
- CIK
- 0001861522
- Website
- kidpik.com
- Similar Companies
- Business
- Kidpik Corp. (Nasdaq: PIK) operates as a subscription-based e-commerce platform specializing in personalized kids' clothing boxes that deliver curated, mix-and-match outfits including apparel, footwear, and accessories for children aged 3 to 16; the service features a try-before-you-buy model where customers pay only for kept items with free styling, shipping, and returns, complemented by an e-commerce store for a la carte purchases. Founded in 2016 and headquartered in New York City, the company designs in-house collections leveraging over three decades of childrenswear expertise from founders including CEO Ezra Dabah, targeting busy parents seeking convenient, high-quality, trend-conscious fashion that empowers kids' personal style and confidence across the United States. Core offerings encompass seasonal subscription boxes with coordinated tops, bottoms, dresses, shoes, and accessories in sizes from 12 months to 16, including husky/slim fits and private label brands; the platform uses style quizzes, data analytics, and stylist input to personalize over 1.3 million boxes shipped to date. In recent developments, Kidpik entered a definitive merger agreement in April 2024 with Nina Footwear Corp., anticipating closure in the first quarter of 2025 under the new Nasdaq ticker NINA to boost revenue, cash flow, and stockholder value while retaining $43 million in net operating loss carryforwards; the company ceased subscription marketing and new inventory purchases to clear existing stock ahead of the combination, reported third quarter 2024 financial results in November 2024, and regained Nasdaq minimum bid price compliance in March 2024.
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Private Credit: Trying To Count The Cockroaches
HTGC 2-WEEK DEADLINE ALERT: Hercules Capital (HTGC) Facing Securities Class Action After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans - Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Oatly Announces Issuance of SEK 1,700 million Nordic Bonds, Entry into SEK 750 million Super Senior Revolving Credit Facility and Intention to Complete Prepayment of Term Loan B, as well as Repurchase and Cancellation of Certain Convertible Senior PIK Notes due 2028
Hercules Capital: Growing Troubles Within Portfolio Warrants Caution
Prospect Capital: PIK Drop A Problem, But Dividend Should Be Safe
Kidpik Announces Suspension of Trading of Common Stock on Nasdaq and its Intention to Appeal
Hertz Announces Receipt of Requisite Consents from Holders to Amend its 12.625% First Lien Senior Secured Notes Due 2029 and 8.000% Exchangeable Senior Second-Lien PIK Notes due 2029 and Expiration of Consent Solicitations
Hertz Announces Consent Solicitations to Amend its 12.625% First Lien Senior Secured Notes Due 2029 and 8.000% Exchangeable Senior Second-Lien PIK Notes due 2029